13 news items
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
TAK
16 May 24
in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
as well as worldwide commercialization.
"At Takeda, we are committed to tackling some of society's most
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
development and be responsible for all global regulatory activities as well as worldwide commercialization. "At Takeda, we are committed
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
Committed to 100-250 Basis Points Core Operating
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people
otm0ijl1l
TAK
22 Apr 24
biopharmaceutical company headquartered in Japan, we are guided by our commitment
gue5ka0cbwhfg0nz0k x9e3sig90ste98da1wauqez2
TAK
18 Apr 24
Business Unit, Takeda. "Our development of a subcutaneous option demonstrates Takeda's commitment to meeting the very real needs of those living
i7l5xmopo0imdzplv f3ksrftmlm7bi
TAK
27 Mar 24
lives and work. As medical teams and individuals in this community, we are committed to promoting the spirit of unlimited support with the goal
e46po3 bbyvfzph2jshr6944bv36eyc53qwfojo5gj
TAK
26 Mar 24
values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet
ucvjhlfpkzt6b8iyevsaprrobfuepkdjh128j78uioioziz
TAK
26 Mar 24
with new possibilities and continue our 70-plus year commitment to the rare disease community."The approval is supported by the totality
81j32e dsb9awr5fjc4da9slgjeqsgt12h31e0l2txgxws9p2zhr8oc
TAK
13 Mar 24
-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees
qp4yjx3td rtq4r0xy3f0p1gb
TAK
26 Feb 24
Vaccine, QDENGA, in multi-dose vials," affirmed Ms. Mahima Datla, managing director at Biological E. Limited. "Takeda's commitment to patient-focused, value
eedmb92krlo1xcuo 7rtk2993xrq1fxecrwe43amr2xj027
TAK
26 Feb 24
headquartered in Japan, committed to discovering and delivering life
- Prev
- 1
- Next